Serge Belanger
Serge Belanger is an analyst at Needham & Co., specializing in biotechnology investments. He has commented on the financial implications of azetukalner's potential market price, highlighting the challenges patients like Rick Bishop may face in affording the medication once it is commercially available.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Needham & Co. analyst Serge Belanger mentioned that Mr. Bishop’s medical bills have wiped out his retirement savings already.
6